Extended Data Fig. 9: The effect of liraglutide administration on glucose metabolism disorders associated with TPN.
From: Total parenteral nutrition impairs glucose metabolism by modifying the gut microbiome
n = 7 animals over 3 independent experiments. (a) Body weight changes of mice during intraperitoneal treatment with liraglutide (* for Chow+ Saline group vs. TPN + Saline group; # for Chow+ Saline group vs TPN + Liraglutide group. P-Values for * were 0.0058, 0.0058, 0.0087, 0.0213, 0.0175, 0.0288 from left to right; P-Values for # were 0.0348, 0.0032, 0.0027, 0.0049, 0.0032, 0.0026 from left to right). b–c. Area under the curve values for intraperitoneal glucose tolerance tests (b) and intraperitoneal insulin tolerance tests (c). (d) Body composition of different groups of mice (P-Values were 4.8E-09, 1.6E-09 between groups from left to right; 7.2E-05 for fat mass in TPN + Saline vs TPN + Liraglutide; 5.3E-05 for lean body mass in TPN + Saline vs TPN + Liraglutide). (e) Serum alanine transaminase (ALT) and aspartate transaminase (AST) concentrations. (f) Liver edema evaluated from the liver/body weight ratio. (g) Serum lipopolysaccharide (LPS) concentration. Data are shown as mean ± S.D. (a), median (solid line) with 1st (lower dotted line) and 3rd (upper dotted line) quartiles in violin plot (b-g). P-Values are determined by Mann-Whitney test (a), Kruskal-Wallis test with correction by Dunnett’s t test (b-g). All statistical tests are two-sided.
